The suite of manuscripts, utilizing key baseline data from the REPRIEVE trial, highlight the impact and prevalence of critical comorbidities among a global cohort of people with HIV.
“The release of this initial baseline data from REPRIEVE will help physicians and researchers to better understand the whole person impact of HIV, and ultimately develop more effective preventions, treatment strategies and guidelines for cardiovascular risk management in this population.” – Steven Grinspoon, MD, Co-Principal Investigator of REPRIEVE
View the full supplement here or read individual manuscripts using the links below:
Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators, Grinspoon et al.
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial, Fichtenbaum et al.
Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial, Looby et al.
Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum, Smeaton et al.
An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitvastatin in Human Immunodeficiency Virus, Overton et al.
Physical Function Impairment and Frailty in Middle-Aged People Living with Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE, Umbleja et al.
Myocardial Steatosis Among Antiretroviral Therapy–Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial, Neilan et al.
